Butyrates role in human health and the current progress towards its clinical application to treat gastrointestinal disease
TWO STUDIES EVALUATE MAINTENANCE THERAPY OPTIONS AFTER ACHIEVING WEIGHT-LOSS GOALS ON GLP DRUGS May 2026 Many patients who have been successful with GLP-1 therapies such as semaglutide (Wegovy) and tirzepatide (Zepbound) wonder what the next steps are after they reach their weight-loss goals
Post-Illness: To enhance recovery
The universal conversion formula Here is the formula that makes every calculation possible: Units to draw = (Desired dose in mg / Concentration in mg per mL) x 100 Example: You want 0.5 mg from a 3.33 mg/mL solution
Nanoparticles Compared with viruses, nanoparticles have lower immunogenicity, longer circulation times, and fewer adverse events
A licensed medical professional travels to your location, performs a health screening, and administers an IV infusion that typically lasts 3060 minutes